HCC1395 Xenograft Model Service for Breast Cancer

The HCC1395 xenograft model offers a highly predictive and translationally relevant in vivo platform for exploring the complex biology of Triple-Negative Breast Cancer (TNBC) and validating next-generation targeted therapeutics. Alfa Cytology delivers a comprehensive, end-to-end HCC1395 xenograft model service, combining optimized inoculation methodologies with scientific rigor to accelerate your preclinical drug discovery pipeline.

Overview of HCC1395 Xenograft Model for Breast Cancer

The HCC1395 cell line is a well-characterized human mammary carcinoma model that represents the aggressive Triple-Negative Breast Cancer (TNBC) phenotype. Derived from a primary ductal carcinoma prior to systemic therapy, this model is fundamentally characterized by the lack of expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). This makes HCC1395 a cornerstone tool for therapeutic areas focused on difficult-to-treat, basal-like breast cancer subsets that do not respond to endocrine approaches or standard HER2-targeted agents.

When established in vivo as a xenograft in immunodeficient mice, HCC1395 cells form tumors with reliable growth kinetics and maintain the histopathological hallmarks of high-grade clinical breast cancers. Genomic and transcriptomic profiling reveals that HCC1395 carries distinct mutations and alterations in DNA damage response pathways and cell cycle checkpoints, providing a highly specific background for testing novel PARP inhibitors, immune-oncology candidates, and combinations targeting genomic instability.

Cell Line Information: HCC1395

The HCC1395 cell line displays a stable epithelial-like morphology in vitro and retains its triple-negative markers seamlessly upon in vivo transplantation.

Alfa Cytology is dedicated to upholding the highest benchmarks of scientific precision across all our tumor modeling operations. Our specialized oncology team utilizes fully authenticated cell lines and carefully monitored protocols to safeguard the genetic and phenotypic stability of the HCC1395 model throughout the lifecycle of your study.

Our Services

Workflow of HCC1395 Xenograft Model Construction

Alfa Cytology executes a standardized and strictly regulated workflow to build and validate the HCC1395 xenograft model:

• Cell Culture & Quality Control: HCC1395 cells are cultivated in specialized growth media. Comprehensive quality controls, including STR profiling and contamination screening, are performed to guarantee high cell viability and phenotypic identity before inoculation.
• Host Adaptation: Standardized immunocompromised mice are selected based on the study design and allowed to acclimate to our controlled, state-of-the-art facility to ensure baseline physiological stability.
• Precision Inoculation: A highly viable, calibrated suspension of HCC1395 cells is prepared and blended with a biological matrix carrier to optimize cell survival. The mixture is precisely injected in vivo via subcutaneous or orthotopic (mammary fat pad) routes.
• Longitudinal Growth Tracking: Following model establishment, tumor growth is tracked systematically using high-precision digital calipers. Animal weights and general welfare behavior are routinely recorded to establish dependable growth kinetics.
• Stratification & Dosing: Once the tumors reach a predetermined, statistically optimal volume range, animals are randomized into therapeutic cohorts to balance group parameters perfectly before dosing protocols begin.

Fig 1. HCC1395 Xenograft Model Construction Workflow

Case Study - HCC1395 Xenograft Model Development

In a recent preclinical trial conducted at Alfa Cytology, the HCC1395 xenograft model was utilized to evaluate the efficacy of a novel cell-cycle checkpoint inhibitor. Our technical team achieved highly reproducible tumor engraftment and exceptionally uniform growth curves across all experimental arms, allowing for an unobstructed and definitive assessment of therapeutic efficacy. The in vivo study successfully demonstrated significant, dose-dependent tumor growth inhibition in the treatment group.

Why Choose Alfa Cytology?

• TNBC Modeling Profiling: Extensive experience handling aggressive receptor-negative human cell lines.
• Technical Reproducibility: Refined inoculation procedures that lead to uniform tumor growth kinetics and minimize intra-group variability.
• Comprehensive Readouts: Full capacity for downstream analysis, including multiparametric flow cytometry, IHC, and PK/PD tissue processing.
• Rigorous Integrity: Scientific approaches aligned with international standards for translational oncology research.

Contact Us

Are you looking to advance your therapeutic pipeline against triple-negative breast cancer using the HCC1395 xenograft platform? The expert scientific team at Alfa Cytology is ready to build a customized study design that fulfills your strategic research goals. Please reach out to us today to speak directly with an oncology specialist, or contact us to request a project-specific consultation and quotation.

For research use only. Not intended for any clinical use.